Full name
A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK3996401 Following Single and Multiple Ascending Doses of GSK4347859 in Healthy Participants
NCT Number
NCT06188507
Geography
Non-US
Locations
United Kingdom
Primary Endpoints
- Part 1 - Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs). Up to Day 15,Part 2 - Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs). Up to Day 30
- Part 1 - Number of Participants with Clinically Significant Changes in Haematology. Up to Day 15
- Part 2 - Number of Participants with Clinically Significant Changes in Haematology. Up to Day 30
- Part 1 - Number of Participants with Clinically Significant Changes in Clinical Chemistry. Up to Day 15
- Part 2 - Number of Participants with Clinically Significant Changes in Clinical Chemistry. Up to Day 30
- Part 1 - Number of Participants with Clinically Significant Changes in Laboratory Values for Urinalysis. Up to Day 15
- Part 2 - Number of Participants with Clinically Significant Changes in Urinalysis. Up to Day 30
- Part 1 - Number of Participants with Clinically Significant Changes in Vital Signs. Up to Day 15
- Part 2 - Number of Participants with Clinically Significant Changes in Vital Signs. Up to Day 30
- Part 1 - Number of Participants with Clinically Significant Changes in 12 Lead Electrocardiogram Readings. Up to Day 15
- Part 2 - Number of Participants with Clinically Significant Changes in 12 Lead Electrocardiogram Readings. Up to Day 30
- Part 1 - Number of Participants with Clinically Significant Changes in 24 Hour Telemetry. Up to Day 2
- Part 2 - Number of Participants with Clinically Significant Changes in 24 Hour Telemetry. Up to Day 15
Order
2
Disease
Version
Phase
1
Status
Recruiting